{"preliminary_commentary":{"by_channel":{"youtube":5,"x_thread":4,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06284564\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["evolocumab","nivolumab"]],"indication":"metastatic renal cell carcinoma","name":"BOOST-RCC","nct_id":"NCT06284564","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=boost-rcc-nct06284564. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"If you are found to be eligible to take part in this study, you will receive evolocumab and nivolumab on Day 1 of each cycle (every 4 weeks). Evolocumab will be given as an injection under the skin. Nivolumab will be given by vein over about 60 minutes.","label":"Evolocumab + Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb","Cancer Prevention Research Institute of Texas","United States Department of Defense"],"completion_date":{"date":"2028-10-01","type":"ESTIMATED"},"conditions":["Metastatic Renal Cell Carcinoma"],"enrollment":{"count":10,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Evolocumab","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":["BMS-936558","Opdivo"],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and adverse events (AEs)","timeFrame":"Through study completion; an average of 1 year"}],"references":[],"start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)","url":"https://clinicaltrials.gov/study/NCT06284564"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/boost-rcc-nct06284564"}